Recombinant Human VEGF-165
Vascular endothelial growth factor-A (VEGF-A) is produced by a wide variety of cell types, including tumor and vascular cells. VEGF-A is a mediator of vascular growth, vascular permeability, and plays a role in stimulating vasodilation via nitric oxide-dependent pathways. VEGF-A has several alternatively spliced isoforms, with VEGF-165 being the most abundant. The VEGF-165 isoform is a secreted protein that acts on receptors VEGFR-1 and VEGFR-2 to modulate endothelial cell proliferation and angiogenesis.
Product images on the website are not representative of actual product, including, but not limited to differences in cap color, tube type, or label format.
Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws.
|Alternate Names||VEGF-A, VPF, glioma-derived endothelial cell mitogen|
|Source||Genetically modified E.coli|
|Predicted Molecular Mass||Dimer, 19.3/38.6 kDa (166/332 aa)|
|AA Sequence||MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR|
|Formulation||Lyophilized from a 0.2 µm filtered solution containing 0.1% Trifluoroacetic Acid (TFA)|
|Product Reconstitution||Sterile water at 0.1 mg/mL|
|Country of Origin||USA|
|Specification*||Method of Determination||Acceptance Criteria|
|Purity||Reducing and Non-Reducing SDS PAGE||≥ 95%|
|Endotoxin||Kinetic LAL||≤ 0.1 EU/µg|
|Biological Activity (ED50)||HUVEC proliferation||≤ 10 ng/mL|
*Lot-specific values for the above specifications are supplied with each product on its corresponding COA. The values provided here are minimum expected values to pass internal requirements.